MX370397B - Vacuna para enfermedad intrauterina. - Google Patents

Vacuna para enfermedad intrauterina.

Info

Publication number
MX370397B
MX370397B MX2015006862A MX2015006862A MX370397B MX 370397 B MX370397 B MX 370397B MX 2015006862 A MX2015006862 A MX 2015006862A MX 2015006862 A MX2015006862 A MX 2015006862A MX 370397 B MX370397 B MX 370397B
Authority
MX
Mexico
Prior art keywords
compositions
pyogenes
whole cells
necrophorum
coli
Prior art date
Application number
MX2015006862A
Other languages
English (en)
Other versions
MX2015006862A (es
Inventor
Carvalho Bicalho Rodrigo
Owen Gilbert Robert
Machado Vinicius
Bicalho Marcela
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of MX2015006862A publication Critical patent/MX2015006862A/es
Publication of MX370397B publication Critical patent/MX370397B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/114Fusobacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • A61J1/18Arrangements for indicating condition of container contents, e.g. sterile condition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0208Specific bacteria not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)

Abstract

La presente invención se refiere a una composición veterinaria para usarse para la profilaxis de metritis puerperal en un rumiante, en donde la composición veterinaria está formulada para ser administrable por vía subcutánea al mamífero rumiante, la composición veterinaria comprende la proteína leucotoxina (LKT) de F. necrophorum, la proteína adhesina fimbrial (FimH) de E.coli tipo 1, y la proteína piolisina de T.pyogenes (PLO).
MX2015006862A 2012-11-29 2013-10-08 Vacuna para enfermedad intrauterina. MX370397B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731333P 2012-11-29 2012-11-29
PCT/US2013/063866 WO2014084964A1 (en) 2012-11-29 2013-10-08 Vaccine for intrauterine disease

Publications (2)

Publication Number Publication Date
MX2015006862A MX2015006862A (es) 2016-06-29
MX370397B true MX370397B (es) 2019-12-11

Family

ID=50828340

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006862A MX370397B (es) 2012-11-29 2013-10-08 Vacuna para enfermedad intrauterina.
MX2019012044A MX2019012044A (es) 2012-11-29 2015-05-29 Vacuna para enfermedad intrauterina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012044A MX2019012044A (es) 2012-11-29 2015-05-29 Vacuna para enfermedad intrauterina.

Country Status (12)

Country Link
US (4) US9533034B2 (es)
EP (2) EP3545970A1 (es)
JP (1) JP6301945B2 (es)
AU (1) AU2013353403B2 (es)
BR (3) BR112015012288B1 (es)
CA (1) CA2893072C (es)
ES (1) ES2718491T3 (es)
HU (1) HUE043129T2 (es)
MX (2) MX370397B (es)
NZ (2) NZ708669A (es)
RU (1) RU2672589C2 (es)
WO (1) WO2014084964A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ708669A (en) * 2012-11-29 2019-12-20 Univ Cornell Vaccine for intrauterine disease
MX2017011648A (es) * 2015-03-12 2017-11-02 Zoetis Services Llc Metodos de piolisina y composiciones.
WO2017083367A1 (en) * 2015-11-09 2017-05-18 Epitopix, Llc Polypeptides of fusobacterium and methods of use
KR102474924B1 (ko) 2020-04-22 2022-12-06 영남대학교 산학협력단 대장균 부착 단백질 FimH를 유효성분으로 포함하는 항암 면역 증강용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133172T2 (de) * 1990-06-07 2003-04-30 Bayer Ag Bacterin zur Behandlung von Lebernekrose verursacht durch F. Necrophorum
AU675234B2 (en) 1992-06-26 1997-01-30 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
US5455034A (en) * 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
ATE506074T1 (de) 1995-06-07 2011-05-15 Univ Kansas State Actinomyces pyogenes und actinomyces pyogenes/fusobakterium necrophorum impfstoffe zur immunisierung von vieh und schafen
US6669940B2 (en) * 2000-04-25 2003-12-30 Kansas University Research Foundation Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
WO2010124085A2 (en) * 2009-04-23 2010-10-28 Cornell University Compositions and methods for preventing and treating uterine disease
NZ708669A (en) * 2012-11-29 2019-12-20 Univ Cornell Vaccine for intrauterine disease

Also Published As

Publication number Publication date
US10821169B2 (en) 2020-11-03
HUE043129T2 (hu) 2019-08-28
CA2893072C (en) 2023-10-03
AU2013353403A1 (en) 2015-07-02
ES2718491T3 (es) 2019-07-02
JP2016507479A (ja) 2016-03-10
EP3545970A1 (en) 2019-10-02
RU2672589C2 (ru) 2018-11-16
US20190358311A1 (en) 2019-11-28
US20180236055A1 (en) 2018-08-23
JP6301945B2 (ja) 2018-03-28
EP2925353A4 (en) 2016-08-10
US9533034B2 (en) 2017-01-03
BR122019025362B1 (pt) 2022-07-26
RU2015125646A (ru) 2017-01-10
NZ708669A (en) 2019-12-20
EP2925353A1 (en) 2015-10-07
US20170100473A1 (en) 2017-04-13
MX2019012044A (es) 2020-01-13
WO2014084964A1 (en) 2014-06-05
US9981032B2 (en) 2018-05-29
MX2015006862A (es) 2016-06-29
NZ754388A (en) 2022-05-27
BR112015012288A2 (pt) 2018-02-06
EP2925353B1 (en) 2019-03-13
AU2013353403B2 (en) 2018-04-19
BR122019025365B1 (pt) 2022-07-26
BR112015012288B1 (pt) 2022-07-26
US20150335725A1 (en) 2015-11-26
CA2893072A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
MY187047A (en) Selective pyy compounds and uses thereof
PH12015502792A1 (en) Crystalline bromodomain inhibitors
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
UA110806C2 (uk) Мікобактеріальна антигенна композиція
MX2019012044A (es) Vacuna para enfermedad intrauterina.
IN2015DN02729A (es)
PH12014501991B1 (en) Phenicol antibacterials
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
IN2014DN06920A (es)
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
NZ723750A (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
BR112014027087A2 (pt) tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells

Legal Events

Date Code Title Description
FG Grant or registration